HSTO — Histogen Share Price
0.000.00%
Last trade - 00:00- $1.28m
- -$4.32m
- $3.77m
- 19
- 31
- 19
- 12
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.15 | ||
| Price to Tang. Book | 0.15 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 42.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -269.72% | ||
| Return on Equity | -134.39% | ||
| Operating Margin | -63442.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 33.59 | 11.45 | 2.06 | 1.03 | 3.77 | 0.01 | n/a | -36.1% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.
Directors
- Steven Mento CHM (69)
- Gail Naughton FDR (65)
- Susan Knudson CFO (57)
- Moya Daniels EVP (53)
- Martin Latterich SVP (54)
- David Crean LED (56)
- Rochelle Fuhrmann IND (51)
- Jonathan Jackson IND (59)
- Daniel Kisner IND (74)
- Brian Satz IND (48)
- Susan Windham-bannister IND (69)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- July 13th, 2005
- Public Since
- July 25th, 2013
- No. of Shareholders
- 101
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 4,271,759
- Address
- 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO, 92121
- Web
- https://histogen.com/
- Phone
- +1 8585263100
- Auditors
- Ernst & Young LLP
Upcoming Events for HSTO
Q2 2024 Histogen Inc Earnings Release
Q3 2024 Histogen Inc Earnings Release
Similar to HSTO
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Histogen share price?
As of Today at 21:09 UTC, shares in Histogen are trading at $0.19. This share price information is delayed by 15 minutes.
How has the Histogen share price performed this year?
Shares in Histogen last closed at $0.19 and the price had moved by -75.95% over the past 365 days. In terms of relative price strength the Histogen share price has underperformed the S&P500 Index by -79.82% over the past year.
What are the analyst and broker recommendations for Histogen?
The overall consensus recommendation for Histogen is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Histogen dividend yield?
Histogen does not currently pay a dividend.
Does Histogen pay a dividend?
Histogen does not currently pay a dividend.
When does Histogen next pay dividends?
Histogen does not currently pay a dividend.
How do I buy Histogen shares?
To buy shares in Histogen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Histogen?
As of the previous close price of $0.19, shares in Histogen had a market capitalisation of $0.81m.
Where are Histogen shares listed?
Here are the trading details for Histogen:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: HSTO
What kind of share is Histogen?
Based on an overall assessment of its quality, value and momentum Histogen is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Histogen share price forecast for 2024?
The analyst consensus target price for shares in Histogen is $2.00. That is 952.63% above the last closing price of $0.19.
Analysts covering Histogen currently have a consensus Earnings Per Share (EPS) forecast of -$2.43 for the next financial year.
What is the trend in the Histogen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Histogen. Over the past six months, its share price has underperformed the S&P500 Index by -45.38%.
As of the last closing price of $0.19, shares in Histogen were trading -53.32% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Histogen PE Ratio?
The Histogen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Histogen?
Histogen's management team is headed by:
- Steven Mento - CHM
- Gail Naughton - FDR
- Susan Knudson - CFO
- Moya Daniels - EVP
- Martin Latterich - SVP
- David Crean - LED
- Rochelle Fuhrmann - IND
- Jonathan Jackson - IND
- Daniel Kisner - IND
- Brian Satz - IND
- Susan Windham-bannister - IND